Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis.
Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Ranallo N, et al. Among authors: sansovini m. Cancers (Basel). 2022 Jun 30;14(13):3231. doi: 10.3390/cancers14133231. Cancers (Basel). 2022. PMID: 35805003 Free PMC article.
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, Donati C, Ianniello A, Matteucci F, Amadori D. Paganelli G, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1845-51. doi: 10.1007/s00259-014-2735-5. Epub 2014 Mar 11. Eur J Nucl Med Mol Imaging. 2014. PMID: 24615468 Clinical Trial.
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Ianniello A, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6. doi: 10.1007/s00259-015-3262-8. Epub 2015 Nov 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26611427 Clinical Trial.
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3. Eur J Nucl Med Mol Imaging. 2017. PMID: 27807661 No abstract available.
Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.
Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G. Nicolini S, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):923-930. doi: 10.1007/s00259-017-3925-8. Epub 2018 Feb 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29387927
39 results